BTK抑制通过抑制氨基酸应答通路使急性淋巴细胞白血病对天冬酰胺酶敏感
研究利用CRISPR/Cas9筛选发现BTK遗传失活或伊布替尼抑制可协同增强天冬酰胺酶(ASNase)对急性淋巴细胞白血病(ALL)的疗效,机制涉及c-Myc介导抑制GCN2活性。该合成致死效应在90%患者来源异种移植(PDX)中观察到,且伊布替尼在PDX模型中改善ASNase治疗反应。
要点
- BTK抑制与ASNase协同在90%患者来源异种移植中观察到。
- 协同机制涉及c-Myc介导抑制GCN2活性。
- 伊布替尼可增强ASNase对ALL的临床疗效。
核心结论
- 伊布替尼可能用于增强ASNase在ALL中的临床疗效。
研究设计与样本
- 利用CRISPR/Cas9筛选鉴定改善ASNase反应的信号中间体,并在患者来源异种移植和鼠PDX模型中验证。
主要发现
- BTK遗传失活和伊布替尼药理抑制均与ASNase强协同,抑制氨基酸应答通路。
- 协同机制涉及c-Myc介导抑制GCN2活性。
- 合成致死相互作用在90%患者来源异种移植中观察到,与基因组亚型无关。
- 伊布替尼在鼠PDX模型中显著改善ASNase治疗反应。
临床怎么用
- 伊布替尼可能作为增强ASNase治疗ALL疗效的联合策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asparaginase (ASNase) therapy has been a mainstay of acute lymphoblastic leukemia (ALL) protocols for decades and shows promise in the treatment of a variety of other cancers. To improve the efficacy of ASNase treatment, we used a CRISPR/Cas9-based screen to identify actionable signaling intermediates that improve the response to ASNase. Both genetic inactivation of Bruton's tyrosine kinase (BTK) and pharmacological inhibition by the BTK inhibitor ibrutinib strongly synergize with ASNase by inhibiting the amino acid response pathway, a mechanism involving c-Myc-mediated suppression of GCN2 activity. This synthetic lethal interaction was observed in 90% of patient-derived xenografts, regardless of the genomic subtype. Moreover, ibrutinib substantially improved ASNase treatment response in a murine PDX model. Hence, ibrutinib may be used to enhance the clinical efficacy of ASNase in ALL. This trial was registered at www.clinicaltrials.gov as # NCT02884453.
引用
- Butler M, van Ingen Schenau DS, Yu J, et al. BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway. Blood. 2021. PMID: 34280258. doi:10.1182/blood.2021011787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。